Executives of Chelsea Therapeutics International Ltd. have their work cut out for them Tuesday, as briefing documents released ahead of the Cardiovascular and Renal Drugs Advisory Committee questioned whether data are sufficient to prove the efficacy of previously rejected neurogenic orthostatic hypotension (NOH) drug Northera (droxidopa).